Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.4, 2001-04, pp. : 573-586

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

By McBurnett Keith Starr H Lynn

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 315-324

Informa Healthcare

Access to resources Recommend Favorite

Adult Attention Deficit Hyperactivity Disorder

Child and Adolescent Psychopharmacology News, Vol. 9, Iss. 8, 2004-12 ,pp. : 1-7

Guilford Publications Inc

Access to resources Recommend Favorite

Trauma and Adult Attention Deficit Hyperactivity Disorder

By Kaya A Taner Y Guclu B Taner E Kaya Y Bahcivan HG Benli IT

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 9-16

Field House Publishing

Access to resources Recommend Favorite

Comorbid Attention Deficit/Hyperactivity Disorder and Substance Use Disorder: Treatment Considerations

Current Drug Abuse Reviews, Vol. 5, Iss. 3, 2012-09 ,pp. : 190-198

Bentham Science Publishers

Access to resources Recommend Favorite

Comorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder

By Kristina Secnik Andrine Swensen Maureen J. Lage

PharmacoEconomics, Vol. 23, Iss. 1, 2005-01 ,pp. : 93-102

Adis International

Access to resources Recommend Favorite